PUBLICATIONS

Publications on Orphan Drugs

  1. Baynam, G, Boycott, KM, Johnson, K, Mckay, L. Language in rare disease: a call for systemic and empathetic action. Lancet. 2026; :. doi: 10.1016/S0140-6736(26)00359-4. PubMed PMID:41765026 .
  2. Miri, M, Abuloha, S, Niu, S, Alshehri, A, Harvey, BP, Svensson, M et al.. Do U.S. Cancer Drug Sales Reflect Clinical Benefit? Evidence from Solid Tumor Drugs from 2008 to 2022. J Cancer Policy. 2026; :100723. doi: 10.1016/j.jcpo.2026.100723. PubMed PMID:41763649 .
  3. Jeon, CW, Yoon, JH, Kim, JE. QbD-Based Formulation Development of Amiodarone Hydrochloride Tablet. Pharmaceutics. 2026;18 (2):. doi: 10.3390/pharmaceutics18020264. PubMed PMID:41755005 PubMed Central PMC12944620.
  4. Afonso, S, Gonçalves, J, Brinca, AT, Rosendo, LM, Rosado, T, Duarte, AP et al.. Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies. Diseases. 2026;14 (2):. doi: 10.3390/diseases14020083. PubMed PMID:41745121 PubMed Central PMC12939546.
  5. Piccaluga, PP, Cimmino, L, Tsekhovska, V, Cimatti, P, Innocenti, C, Seidenari, S et al.. From Cell Lines to Avatars: Charting the Future of Preclinical Modeling in T-Cell Malignancies. Cells. 2026;15 (4):. doi: 10.3390/cells15040368. PubMed PMID:41744811 PubMed Central PMC12939640.
  6. Li, Y, Liu, Z, Huang, R, Liu, Y. The imperative for national legislation on rare diseases in China: A policy review and call to action. Intractable Rare Dis Res. 2026;15 (1):4-10. doi: 10.5582/irdr.2025.01058. PubMed PMID:41744018 PubMed Central PMC12932008.
  7. Tang, W. From system building to global engagement: Current significance of and future directions for rare disease research in China. Intractable Rare Dis Res. 2026;15 (1):1-3. doi: 10.5582/irdr.2026.01015. PubMed PMID:41744017 PubMed Central PMC12932007.
  8. Hu, S. Progress in the research and pharmacoeconomic evaluation of drugs and devices for rare diseases in China. Intractable Rare Dis Res. 2026;15 (1):11-16. doi: 10.5582/irdr.2025.01071. PubMed PMID:41744015 PubMed Central PMC12932010.
  9. Rosenberg, N, Hollak, CEM, Haverhoek, VA, Stoyanova-Beninska, V, Pasmooij, AMG, de Visser, SJ et al.. Tracing the path of non-industry-driven medicine development for rare diseases through regulatory interactions at the European Medicines Agency. Drug Discov Today. 2026; :104631. doi: 10.1016/j.drudis.2026.104631. PubMed PMID:41722896 .
  10. Fletcher, EP, Kim, C, Mei, H, AbuAsal, B, Samuels, S, Madabushi, R et al.. Informing Dose for Pediatric Rare Diseases-A Survey of Recent Orphan Drugs Approvals. Clin Transl Sci. 2026;19 (2):e70503. doi: 10.1111/cts.70503. PubMed PMID:41707029 PubMed Central PMC12916015.
  11. Marcellusi, A, Maggioni, AP, Mandorino, AL, Caprari, F, Marzona, I, Jommi, C et al.. [Not Available]. Glob Reg Health Technol Assess. 2026;13 :49-54. doi: 10.33393/grhta.2026.3604. PubMed PMID:41705260 PubMed Central PMC12908649.
  12. Hollak, CEM, Rosenberg, N, Post, C, Stolwijk, N, Manders, E, Schoenmakers, D et al.. Medicine Development and Access for Rare Diseases: Can We Do Better?. J Inherit Metab Dis. 2026;49 (2):e70146. doi: 10.1002/jimd.70146. PubMed PMID:41702420 PubMed Central PMC12912821.
  13. Jiao, Y, Yuan, F, Liu, T, Han, J, Sun, J, Chu, S et al.. Patent Analysis Perspectives on China's Orphan Drug R&D: Status and Technology Characteristics. Ther Innov Regul Sci. 2026; :. doi: 10.1007/s43441-026-00927-x. PubMed PMID:41697637 .
  14. van der Zanden, TM, Mooij, MG, de Hoog, M, de Wildt, SN. Beyond the label: Rethinking off-label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy. Br J Clin Pharmacol. 2026; :. doi: 10.1002/bcp.70461. PubMed PMID:41693205 .
  15. Nakai, K. Japan's Pharmaceutical Regulatory Reform to Overcome Drug Loss Issue. Ther Innov Regul Sci. 2026; :. doi: 10.1007/s43441-026-00928-w. PubMed PMID:41691137 .
  16. Bouwman, L, Leufkens, H, Sepodes, B, Torre, C. Safety population size and duration of exposure prior to approval of new medicines: A database analysis of medicines centralised approved in the European Union between 2011 and 2023. PLoS One. 2026;21 (2):e0342698. doi: 10.1371/journal.pone.0342698. PubMed PMID:41662378 PubMed Central PMC12885265.
  17. Khoshkhoo, S, Bae, M, Wang, Y, Tillett, A, Ramirez, RB, Finander, B et al.. Activating Ras-MAPK pathway variants drive hippocampal clonal competition in human epilepsy. bioRxiv. 2026; :. doi: 10.64898/2026.01.26.701822. PubMed PMID:41659639 PubMed Central PMC12873922.
  18. Manders, EA, van Der Wel, V, Schlingemann, R, Hollak, CEM, de Visser, SJ. Repurposing biosimilars, rethinking costs: a framework for sustainable drug pricing for repurposed bevacizumab for intravitreal injections. Eur J Health Econ. 2026; :. doi: 10.1007/s10198-025-01891-3. PubMed PMID:41653377 .
  19. Walter, E, Ghinelli, F, Goyer, I, Leone, M, Pirracchio, R. Cost-effectiveness of vasopressin in the treatment of septic shock: insights from a European societal perspective. J Med Econ. 2026;29 (1):319-333. doi: 10.1080/13696998.2026.2622854. PubMed PMID:41637478 .
  20. Papanicolas, I, Wouters, OJ, Sawaya, T, Han, J, Wei, J, Naci, H et al.. Review Times For New Drugs And Submission Delays Among The FDA And 4 International Regulators, 2014-22. Health Aff (Millwood). 2026;45 (2):184-192. doi: 10.1377/hlthaff.2025.00595. PubMed PMID:41628382 .
Search PubMed